OBJECTIVE: To determine the correspondence of in vivo quantitative estimates of brain uptake of fluorine 18-labeled flutemetamol with immunohistochemical estimates of amyloid levels in patients who underwent previous biopsy. DESIGN: Cross-sectional study of ¹⁸F-flutemetamol positron emission tomography (PET) findings in patients with prior cortical biopsy specimen stained for the presence or absence of amyloid plaques. SETTING: University hospital. Patients Seven patients who previously had a prior right frontal cortical biopsy at the site of ventriculoperitoneal placement for presumed normal pressure hydrocephalus were recruited. Inclusion criteria included an adequate biopsy specimen for detection and quantification of β-amyloid pathology and age older than 50 years. Intervention All patients underwent an ¹⁸F-flutemetamol PET scan. MAIN OUTCOME MEASURES: Quantitative measures of ¹⁸F-flutemetamol uptake (standardized uptake value ratio, a ratio of mean target cortex activity divided by that in a cerebellar reference region) were made at a location contralateral to the biopsy site and compared with estimates of amyloid load based on immunohistochemical and histological staining. RESULTS: There was complete agreement between visual reads of ¹⁸F-flutemetamol PET scans (3 blinded readers with majority rule) and histology. A regression model, including time from biopsy as a covariate, demonstrated a significant relationship (P = .01) between ¹⁸F-flutemetamol uptake and percentage of area of amyloid measured by a monoclonal antibody raised against amyloid (NAB228). Similar results were found with the amyloid-specific monoclonal antibody 4G8 and Thioflavin S. CONCLUSION: To our knowledge, these data are the first to demonstrate the concordance of ¹⁸F-flutemetamol PET imaging with histopathology, supporting its sensitivity to detect amyloid and potential use in the study and detection of Alzheimer disease.
OBJECTIVE: To determine the correspondence of in vivo quantitative estimates of brain uptake of fluorine 18-labeled flutemetamol with immunohistochemical estimates of amyloid levels in patients who underwent previous biopsy. DESIGN: Cross-sectional study of ¹⁸F-flutemetamol positron emission tomography (PET) findings in patients with prior cortical biopsy specimen stained for the presence or absence of amyloid plaques. SETTING: University hospital. Patients Seven patients who previously had a prior right frontal cortical biopsy at the site of ventriculoperitoneal placement for presumed normal pressure hydrocephalus were recruited. Inclusion criteria included an adequate biopsy specimen for detection and quantification of β-amyloid pathology and age older than 50 years. Intervention All patients underwent an ¹⁸F-flutemetamol PET scan. MAIN OUTCOME MEASURES: Quantitative measures of ¹⁸F-flutemetamol uptake (standardized uptake value ratio, a ratio of mean target cortex activity divided by that in a cerebellar reference region) were made at a location contralateral to the biopsy site and compared with estimates of amyloid load based on immunohistochemical and histological staining. RESULTS: There was complete agreement between visual reads of ¹⁸F-flutemetamol PET scans (3 blinded readers with majority rule) and histology. A regression model, including time from biopsy as a covariate, demonstrated a significant relationship (P = .01) between ¹⁸F-flutemetamol uptake and percentage of area of amyloid measured by a monoclonal antibody raised against amyloid (NAB228). Similar results were found with the amyloid-specific monoclonal antibody 4G8 and Thioflavin S. CONCLUSION: To our knowledge, these data are the first to demonstrate the concordance of ¹⁸F-flutemetamol PET imaging with histopathology, supporting its sensitivity to detect amyloid and potential use in the study and detection of Alzheimer disease.
Authors: Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio Journal: N Engl J Med Date: 2006-12-21 Impact factor: 91.245
Authors: Cyrus A Raji; James T Becker; Nicholas D Tsopelas; Julie C Price; Chester A Mathis; Judith A Saxton; Brian J Lopresti; Jessica A Hoge; Scott K Ziolko; Steven T DeKosky; William E Klunk Journal: J Neurosci Methods Date: 2008-05-16 Impact factor: 2.390
Authors: Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks Journal: Ann Neurol Date: 2010-09 Impact factor: 10.422
Authors: Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman Journal: Lancet Neurol Date: 2010-02-26 Impact factor: 44.182
Authors: Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg Journal: Brain Date: 2006-07-19 Impact factor: 13.501
Authors: Sandhitsu R Das; Dawn Mechanic-Hamilton; Marc Korczykowski; John Pluta; Simon Glynn; Brian B Avants; John A Detre; Paul A Yushkevich Journal: Hippocampus Date: 2009-06 Impact factor: 3.899
Authors: Nicolaas P L G Verhoeff; Alan A Wilson; Shinichiro Takeshita; Liat Trop; Doug Hussey; Kernjit Singh; Hank F Kung; Mei-Ping Kung; Sylvain Houle Journal: Am J Geriatr Psychiatry Date: 2004 Nov-Dec Impact factor: 4.105
Authors: Myria Petrou; Ben A Dwamena; Bradley R Foerster; Mark P MacEachern; Nicolaas I Bohnen; Martijn Ltm Müller; Roger L Albin; Kirk A Frey Journal: Mov Disord Date: 2015-04-16 Impact factor: 10.338
Authors: Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Kevin P Horn; Kelli M Rasmussen; Britney E Beardmore; Lance D Burrell; Kevin Duff; John M Hoffman Journal: Am J Alzheimers Dis Other Demen Date: 2017-04-12 Impact factor: 2.035
Authors: Kevin Duff; Norman L Foster; Kathryn Dennett; Dustin B Hammers; Lauren V Zollinger; Paul E Christian; Regan I Butterfield; Britney E Beardmore; Angela Y Wang; Kathryn A Morton; John M Hoffman Journal: Arch Clin Neuropsychol Date: 2013-06-30 Impact factor: 2.813